1. Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson’s disease in rats 
Baninder Kaur, Atish Prakash 
Pathophysiology 
Volume 24, Issue 2, Pages (June 2017)
DOI: /j.pathophys
Copyright © 2017 Elsevier B.V. Terms and Conditions

2. Fig. 1 Study protocol Design.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

3. Fig. 2
Effect of ceftriaxone and its combination with glutamate modulators on body weight in MPTP-administered rats.
Data was expressed as mean±S.E.M.’s. aP≤0.01 as compared to sham control; bP<0.05 as compared to MPTP-treated group; cP<0.05 as compared to CFX (100); dP<0.05 as compared to MEM (20). (Two-way ANOVA followed by Bonferroni's test). MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CFX: Ceftriaxone, MEM: Memantine, DHK: Dihydrokainate.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

4. Fig. 3
Effect of ceftriaxone and its combination with glutamate modulators on locomotor activity in MPTPadministeredrats.
Data was expressed as mean±S.E.M. aP≤0.01 as compared to sham control; bP<0.05 as compared to MPTP-treated group; cP<0.05 as compared to CFX (100); dP<0.05 as compared to MEM (20); eP<0.05 as compared to DHK (200nm). (Two-way ANOVA followed by Bonferroni's test). MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CFX: Ceftriaxone, MEM: Memantine, DHK: Dihydrokainate.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

5. Fig. 4
Effect of ceftriaxone and its combination with glutamate modulators on rotarod and grip strength in MPTP administered rats.
Data was expressed as mean±S.E.M. aP≤0.01 as compared to sham control; bP<0.05 as compared to MPTP-treated group; cP<0.05 as compared to CFX (100); dP<0.05 as compared to MEM (20). (Two-way ANOVA followed by Bonferroni's test). MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CFX: Ceftriaxone, MEM: Memantine, DHK: Dihydrokainate.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

6. Fig. 5
Effect of ceftriaxone and its combination with glutamate modulators on time taken to cross straight run way and foot error on narrow beam walk in MPTP administered rats.
Data was expressed as mean±S.E.M. aP≤0.01 as compared to sham control; bP<0.05 as compared to MPTP-treated group; cP<0.05 as compared to CFX (100); dP<0.05 as compared to MEM (20). (Two-way ANOVA followed by Bonferroni’s test). MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CFX: Ceftriaxone, MEM: Memantine, DHK: Dihydrokainate.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

7. Fig. 6
Effect of ceftriaxone and its combination with glutamate modulators on pro-inflammatory markers {(A) NFκB, (B) TNF-α and(C) IL-1 β} levels and (D) BDNF in MPTP induced PD in rats.
Data was expressed as mean±S.E.M. aP≤0.01 as compared to sham control; bP<0.05 as compared to MPTP-treated group; cP<0.05 as compared to CFX (100); dP<0.05 as compared to MEM (20). (One-way ANOVA followed by Bonferroni’s test). MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CFX: Ceftriaxone, MEM: Memantine, DHK: Dihydrokainate.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

8. Fig. 7
Schematic representation of the mechanism action of Ceftriaxone against MPTP model of Parkinson’s disease in rats.
Pathophysiology  , 71-79DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions